Who Paid My Doc
Michael Reed
Cardiovascular Disease Missoula, MT Medical Doctor
NPI 1346396967 CMS profile 243029
500 West Broadway, St. Patrick Hospital, Missoula, MT 59802
General payments
$8,151
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$629,132
Through program year 2025, Michael Reed of Missoula, MT is reported in the CMS Open Payments database as having received $8,151 across 133 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $629,132 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 78th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,332 | 23 | |
| 2024 | General | $675 | 15 | |
| 2023 | General | $972 | 22 | |
| 2022 | General | $1,496 | 16 | |
| 2021 | General | $1,208 | 25 | |
| 2020 | General | $311 | 11 | |
| 2019 | General | $1,156 | 21 |
Beside peers
- Michael Reed
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to Michael Reed were reported at $2,332. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | Michael Reed | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $1,156 | $450 | $127–$1,392 | $163 |
| 2020 | $311 | $242 | $77–$751 | $114 |
| 2021 | $1,208 | $335 | $101–$1,037 | $132 |
| 2022 | $1,496 | $395 | $121–$1,211 | $149 |
| 2023 | $972 | $443 | $136–$1,283 | $160 |
| 2024 | $675 | $450 | $136–$1,323 | $164 |
| 2025 | $2,332 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 14 drugsPart D claims
619
Drug cost
$61,655
Branded share of claims
40.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Brilinta Ticagrelor | Brand | 27 | $25,204 | |
| Eliquis Apixaban | Brand | 12 | $14,886 | |
| Xarelto Rivaroxaban | Brand | 11 | $13,867 | |
| Clopidogrel Clopidogrel Bisulfate | Brand | 189 | $2,019 | |
| Prasugrel Hcl | Generic | 27 | $1,822 | |
| Atorvastatin Calcium | Generic | 136 | $1,650 | |
| Metoprolol Succinate | Generic | 66 | $929 | |
| Losartan Potassium | Generic | 25 | $288 | |
| Lisinopril | Generic | 26 | $212 | |
| Furosemide | Generic | 28 | $182 |
The 10 drugs with the highest cost, of 14 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 76 billing codesPaid by Medicare
$225,554
Medicare patients
988
Services billed
2,043
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Ischemic heart disease | 55% | |
| Arthritis | 47% | |
| Atrial fibrillation | 44% | |
| Heart failure | 38% | |
| Diabetes | 28% | |
| Chronic kidney disease | 27% | |
| Depression | 25% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
133 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in Montana
Benjamin Plank
Cardiovascular Disease · Billings, MT
Alrich Gray
Cardiovascular Disease · Great Falls, MT
Robert Mitchell
Cardiovascular Disease · Kalispell, MT
Jocelyn Spoon
Cardiovascular Disease · Missoula, MT
Patricia Kelly
Cardiovascular Disease · Missoula, MT
Joseph Apostol
Cardiovascular Disease · Billings, MT
Related records
Cardiovascular Disease in Montana
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in Montana
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.